GlassScriptPhysician profile
Heath W Hampton
NPI 1750388500
$4,316.16
in general payments reported to CMS, 2019-2025
27 companies · $892 in 2025
The $892 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $498 · 2020: $213 · 2021: $397 · 2022: $562 · 2023: $1,003 · 2024: $750 · 2025: $892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,645.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,645.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $506.72 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $451.64 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $425.59 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Astrazeneca Pharmaceuticals LP | $391.47 | 2019-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $365.94 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $332.07 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $226.40 | 2019-2021 | |
| Glaxosmithkline, LLC. | $178.49 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $176.81 | 2019-2025 | Otezla, Repatha, Repatha |
| Otsuka America Pharmaceutical, INC. | $159.85 | 2022-2024 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $149.04 | 2021-2025 | |
| Dexcom, INC. | $126.65 | 2022-2023 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $101.67 | 2020-2024 | Belsomra, Steglatro, Gardasil |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $100.43 | 2023-2025 | Xifaxan, Trulance |
| Abbott Laboratories | $84.42 | 2023-2025 | Freestyle Libre 3 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $76.31 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $74.56 | 2019-2025 | |
| Xeris Pharmaceuticals, INC. | $66.41 | 2023 | Gvoke Hypopen |
| Phathom Pharmaceuticals, INC. | $62.36 | 2025 | Voquezna |
| Exact Sciences Corporation | $52.48 | 2023-2024 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $48.88 | 2025 | Nexletol |
| Boston Scientific Corporation | $38.44 | 2025 | General - Pain Management |
| Lundbeck LLC | $36.92 | 2023 | Rexulti |
| Amarin Pharma, INC. | $28.62 | 2019 | |
| Sumitomo Pharma America, INC. | $25.00 | 2025 | Gemtesa |
| Mylan Specialty L.P. | $14.99 | 2022 | |
| Sunovion Pharmaceuticals INC. | $14.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heath Hampton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.